bioAffinity Technologies (BIAF) Competitors $1.56 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$1.56 0.00 (-0.06%) As of 05/22/2026 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BIAF vs. PMEC, XBP, KPLT, GRNQ, and PSQHShould you buy bioAffinity Technologies stock or one of its competitors? MarketBeat compares bioAffinity Technologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with bioAffinity Technologies include Primech (PMEC), XBP Global (XBP), Katapult (KPLT), Greenpro Capital (GRNQ), and PSQ (PSQH). These companies are all part of the "business services" industry. BIAF vs. PMECBIAF vs. XBPBIAF vs. KPLTBIAF vs. GRNQBIAF vs. PSQHHow does bioAffinity Technologies compare to Primech?Primech (NASDAQ:PMEC) and bioAffinity Technologies (NASDAQ:BIAF) are both small-cap business services companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk. Which has more volatility & risk, PMEC or BIAF? Primech has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market. Comparatively, bioAffinity Technologies has a beta of -1.19, suggesting that its stock price is 219% less volatile than the broader market. Is PMEC or BIAF more profitable? Primech has a net margin of 0.00% compared to bioAffinity Technologies' net margin of -280.53%. Primech's return on equity of 0.00% beat bioAffinity Technologies' return on equity.Company Net Margins Return on Equity Return on Assets PrimechN/A N/A N/A bioAffinity Technologies -280.53%-285.75%-143.71% Does the media favor PMEC or BIAF? In the previous week, Primech's average media sentiment score of 0.00 equaled bioAffinity Technologies'average media sentiment score. Company Overall Sentiment Primech Neutral bioAffinity Technologies Neutral Do institutionals & insiders have more ownership in PMEC or BIAF? 88.1% of Primech shares are owned by institutional investors. Comparatively, 1.6% of bioAffinity Technologies shares are owned by institutional investors. 2.7% of bioAffinity Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has preferable earnings and valuation, PMEC or BIAF? Primech has higher revenue and earnings than bioAffinity Technologies. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrimech$74.35M0.41-$1.94MN/AN/AbioAffinity Technologies$5.61M1.26-$14.91M-$11.77N/A Do analysts recommend PMEC or BIAF? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Primech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00bioAffinity Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SummaryPrimech beats bioAffinity Technologies on 7 of the 9 factors compared between the two stocks.How does bioAffinity Technologies compare to XBP Global?bioAffinity Technologies (NASDAQ:BIAF) and XBP Global (NASDAQ:XBP) are both small-cap business services companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. Which has higher earnings & valuation, BIAF or XBP? XBP Global has higher revenue and earnings than bioAffinity Technologies. XBP Global is trading at a lower price-to-earnings ratio than bioAffinity Technologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatiobioAffinity Technologies$5.61M1.26-$14.91M-$11.77N/AXBP Global$148.33M0.21$1.10B-$3.28N/A Do insiders & institutionals hold more shares of BIAF or XBP? 1.6% of bioAffinity Technologies shares are owned by institutional investors. Comparatively, 15.7% of XBP Global shares are owned by institutional investors. 2.7% of bioAffinity Technologies shares are owned by company insiders. Comparatively, 31.4% of XBP Global shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is BIAF or XBP more profitable? XBP Global has a net margin of 130.26% compared to bioAffinity Technologies' net margin of -280.53%. XBP Global's return on equity of 1,645.47% beat bioAffinity Technologies' return on equity.Company Net Margins Return on Equity Return on Assets bioAffinity Technologies-280.53% -285.75% -143.71% XBP Global 130.26%1,645.47%146.77% Does the media prefer BIAF or XBP? In the previous week, XBP Global had 2 more articles in the media than bioAffinity Technologies. MarketBeat recorded 2 mentions for XBP Global and 0 mentions for bioAffinity Technologies. XBP Global's average media sentiment score of 1.95 beat bioAffinity Technologies' score of 0.00 indicating that XBP Global is being referred to more favorably in the news media. Company Overall Sentiment bioAffinity Technologies Neutral XBP Global Very Positive Do analysts recommend BIAF or XBP? XBP Global has a consensus target price of $5.00, suggesting a potential upside of 86.57%. Given XBP Global's stronger consensus rating and higher possible upside, analysts clearly believe XBP Global is more favorable than bioAffinity Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score bioAffinity Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00XBP Global 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more risk and volatility, BIAF or XBP? bioAffinity Technologies has a beta of -1.19, indicating that its share price is 219% less volatile than the broader market. Comparatively, XBP Global has a beta of -0.39, indicating that its share price is 139% less volatile than the broader market. SummaryXBP Global beats bioAffinity Technologies on 14 of the 16 factors compared between the two stocks.How does bioAffinity Technologies compare to Katapult?Katapult (NASDAQ:KPLT) and bioAffinity Technologies (NASDAQ:BIAF) are both small-cap business services companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends. Which has better earnings and valuation, KPLT or BIAF? Katapult has higher revenue and earnings than bioAffinity Technologies. bioAffinity Technologies is trading at a lower price-to-earnings ratio than Katapult, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKatapult$291.76M0.10$1.37M$1.155.30bioAffinity Technologies$5.61M1.26-$14.91M-$11.77N/A Do institutionals & insiders have more ownership in KPLT or BIAF? 26.8% of Katapult shares are owned by institutional investors. Comparatively, 1.6% of bioAffinity Technologies shares are owned by institutional investors. 8.0% of Katapult shares are owned by company insiders. Comparatively, 2.7% of bioAffinity Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has more risk and volatility, KPLT or BIAF? Katapult has a beta of 1.56, meaning that its stock price is 56% more volatile than the broader market. Comparatively, bioAffinity Technologies has a beta of -1.19, meaning that its stock price is 219% less volatile than the broader market. Does the media favor KPLT or BIAF? In the previous week, Katapult had 4 more articles in the media than bioAffinity Technologies. MarketBeat recorded 4 mentions for Katapult and 0 mentions for bioAffinity Technologies. Katapult's average media sentiment score of 0.31 beat bioAffinity Technologies' score of 0.00 indicating that Katapult is being referred to more favorably in the media. Company Overall Sentiment Katapult Neutral bioAffinity Technologies Neutral Is KPLT or BIAF more profitable? Katapult has a net margin of 2.48% compared to bioAffinity Technologies' net margin of -280.53%. Katapult's return on equity of -16.24% beat bioAffinity Technologies' return on equity.Company Net Margins Return on Equity Return on Assets Katapult2.48% -16.24% 7.63% bioAffinity Technologies -280.53%-285.75%-143.71% Do analysts rate KPLT or BIAF? Katapult currently has a consensus price target of $10.00, indicating a potential upside of 63.93%. Given Katapult's stronger consensus rating and higher probable upside, analysts plainly believe Katapult is more favorable than bioAffinity Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Katapult 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50bioAffinity Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SummaryKatapult beats bioAffinity Technologies on 14 of the 15 factors compared between the two stocks.How does bioAffinity Technologies compare to Greenpro Capital?Greenpro Capital (NASDAQ:GRNQ) and bioAffinity Technologies (NASDAQ:BIAF) are both small-cap business services companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability. Which has more volatility and risk, GRNQ or BIAF? Greenpro Capital has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market. Comparatively, bioAffinity Technologies has a beta of -1.19, meaning that its stock price is 219% less volatile than the broader market. Do analysts rate GRNQ or BIAF? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Greenpro Capital 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00bioAffinity Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Do institutionals & insiders believe in GRNQ or BIAF? 0.9% of Greenpro Capital shares are held by institutional investors. Comparatively, 1.6% of bioAffinity Technologies shares are held by institutional investors. 39.7% of Greenpro Capital shares are held by company insiders. Comparatively, 2.7% of bioAffinity Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media favor GRNQ or BIAF? In the previous week, Greenpro Capital had 1 more articles in the media than bioAffinity Technologies. MarketBeat recorded 1 mentions for Greenpro Capital and 0 mentions for bioAffinity Technologies. Greenpro Capital's average media sentiment score of 0.75 beat bioAffinity Technologies' score of 0.00 indicating that Greenpro Capital is being referred to more favorably in the media. Company Overall Sentiment Greenpro Capital Positive bioAffinity Technologies Neutral Is GRNQ or BIAF more profitable? Greenpro Capital has a net margin of -153.32% compared to bioAffinity Technologies' net margin of -280.53%. Greenpro Capital's return on equity of -31.13% beat bioAffinity Technologies' return on equity.Company Net Margins Return on Equity Return on Assets Greenpro Capital-153.32% -31.13% -25.47% bioAffinity Technologies -280.53%-285.75%-143.71% Which has better valuation & earnings, GRNQ or BIAF? Greenpro Capital has higher earnings, but lower revenue than bioAffinity Technologies. Greenpro Capital is trading at a lower price-to-earnings ratio than bioAffinity Technologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGreenpro Capital$2.07M12.94-$2.98M-$0.39N/AbioAffinity Technologies$5.61M1.26-$14.91M-$11.77N/A SummaryGreenpro Capital beats bioAffinity Technologies on 10 of the 13 factors compared between the two stocks.How does bioAffinity Technologies compare to PSQ?bioAffinity Technologies (NASDAQ:BIAF) and PSQ (NYSE:PSQH) are both small-cap business services companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends. Which has stronger valuation and earnings, BIAF or PSQH? bioAffinity Technologies has higher earnings, but lower revenue than PSQ. PSQ is trading at a lower price-to-earnings ratio than bioAffinity Technologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatiobioAffinity Technologies$5.61M1.26-$14.91M-$11.77N/APSQ$18.22M1.60-$36.61M-$0.81N/A Do analysts rate BIAF or PSQH? PSQ has a consensus target price of $3.50, suggesting a potential upside of 484.80%. Given PSQ's stronger consensus rating and higher probable upside, analysts clearly believe PSQ is more favorable than bioAffinity Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score bioAffinity Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00PSQ 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media refer more to BIAF or PSQH? In the previous week, PSQ's average media sentiment score of 0.46 beat bioAffinity Technologies' score of 0.00 indicating that PSQ is being referred to more favorably in the news media. Company Overall Sentiment bioAffinity Technologies Neutral PSQ Neutral Which has more risk and volatility, BIAF or PSQH? bioAffinity Technologies has a beta of -1.19, indicating that its share price is 219% less volatile than the broader market. Comparatively, PSQ has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market. Is BIAF or PSQH more profitable? PSQ has a net margin of -143.15% compared to bioAffinity Technologies' net margin of -280.53%. PSQ's return on equity of -217.16% beat bioAffinity Technologies' return on equity.Company Net Margins Return on Equity Return on Assets bioAffinity Technologies-280.53% -285.75% -143.71% PSQ -143.15%-217.16%-53.86% Do insiders and institutionals believe in BIAF or PSQH? 1.6% of bioAffinity Technologies shares are held by institutional investors. Comparatively, 17.3% of PSQ shares are held by institutional investors. 2.7% of bioAffinity Technologies shares are held by insiders. Comparatively, 22.1% of PSQ shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryPSQ beats bioAffinity Technologies on 13 of the 15 factors compared between the two stocks. Get bioAffinity Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for BIAF and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BIAF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BIAF vs. The Competition ExportMetricbioAffinity TechnologiesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.08M$3.37B$6.43B$12.32BDividend YieldN/A2.26%2.76%5.28%P/E Ratio-0.1318.9121.0125.66Price / Sales1.26329.35615.84111.99Price / CashN/A125.1743.4956.67Price / Book1.937.0910.377.14Net Income-$14.91M$24.45M$3.57B$335.98M7 Day Performance-7.42%5.45%6.01%3.56%1 Month Performance-30.04%2.43%3.52%2.54%1 Year Performance-80.15%62.98%34.13%35.05% bioAffinity Technologies Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BIAFbioAffinity Technologies0.0807 of 5 stars$1.56flatN/A-80.1%$7.08M$5.61MN/A10Gap UpPMECPrimech0.2316 of 5 stars$0.79-0.1%N/A-32.2%$30.31M$74.35MN/A2,806Gap UpXBPXBP Global4.1014 of 5 stars$2.47+19.3%$5.00+102.4%-75.2%$29.07M$148.33MN/A10,600Positive NewsHigh Trading VolumeKPLTKatapult2.3798 of 5 stars$6.05-4.7%$10.00+65.3%-31.8%$28.86M$291.76M5.26130GRNQGreenpro Capital1.0954 of 5 stars$1.55-7.2%N/A+32.1%$27.95M$2.07MN/A60 Related Companies and Tools Related Companies Primech Competitors XBP Global Competitors Katapult Competitors Greenpro Capital Competitors PSQ Competitors GEE Group Competitors Diginex Competitors Quest Resource Competitors Mobiquity Technologies Competitors Zenta Group Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BIAF) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding bioAffinity Technologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share bioAffinity Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
